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Integrin a7 is a functional cancer stem cell surface
marker in oesophageal squamous cell carcinoma
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Dan Xie7 & Xin-Yuan Guan1,2,7
Non-CG methylation has been associated with stemness regulation in embryonic stem cells.
By comparing differentially expressed genes affected by non-CG methylation between tumour
and corresponding non-tumour tissues in oesophageal squamous cell carcinoma (OSCC),
we ﬁnd that Integrin a7 (ITGA7) is characterized as a potential cancer stem cell (CSC) marker.
Clinical data show that a high frequency of ITGA7þ cells in OSCC tissues is signiﬁcantly
associated with poor differentiation, lymph node metastasis and worse prognosis. Functional
studies demonstrate that both sorted ITGA7þ cells and ITGA7 overexpressing cells display
enhanced stemness features, including elevated expression of stemness-associated genes
and epithelial–mesenchymal transition features, as well as increased abilities to self-renew,
differentiate and resist chemotherapy. Mechanistic studies ﬁnd that ITGA7 regulates CSC
properties through the activation of the FAK-mediated signalling pathways. As knockdown
of ITGA7 can effectively reduce the stemness of OSCC cells, ITGA7 could be a potential
therapeutic target in OSCC treatment.
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O
esophageal squamous cell carcinoma (OSCC), the major
histologic subtype of oesophageal cancer, is one of the
most common malignancies and ranked as the sixth
leading cause of cancer death worldwide1. OSCC is characterized
by its remarkable geographic distribution with particularly high-
risks in Northern China2. Despite advances in diagnosis and
treatment of OSCC, the 5-year survival rate after curative surgery
is only 20–30%, mainly due to tumour metastasis, tumour
recurrence and chemoresistance1. Recently, increasing evidence
suggests that cancer stem cells (CSCs) represent an important
subset of tumour cells that are responsible for tumour metastasis,
tumour recurrence and chemoresistance3–6. CSCs are a subset of
cancer cells that are biologically distinct from the others and have
stem cell-like features7. CSC has now been showed to exist in
different tumour types including breast cancer8, hepatocellular
carcinoma9 and OSCC10. Currently, most CSCs are marked by
either cell surface markers (for example, CD90 or CD133) or
functional properties (for example, site population)11. In OSCC,
surface proteins CD90 (ref. 10), CD44 (ref. 12), and p75NTR
(ref. 13), have previously been used to phenotypically mark and
functionally deﬁne oesophageal CSC subsets in cell lines and
clinical samples. These markers can markedly enrich the
oesophageal CSC subpopulation, however, the purity of CSCs is
unknown. In addition, the roles of these markers in stemness
regulation and CSC maintenance are rarely understood.
A recent study by Lister et al. found that nearly 25% of all
methylated sites identiﬁed in embryonic stem cells (ESC) are in a
non-CG context14. Non-CG methylation disappears on induced
differentiation of ESCs and can be restored in induced pluripotent
stem cells (iPSC)14. Another report also demonstrated that non-
CG methylation appears to be conﬁned to stem cells15. As CSCs
share many common properties with stem cells16,17, we
hypothesize that non-CG methylation also predominantly exists
in CSCs but not in other differentiated cancer cells. To test this,
we ﬁrst selected 10 stemness-associated genes with differential
non-CG methylation between ESC and ﬁbroblast from Lister
et al.’s report for preliminary study in OSCC cell lines and clinical
specimens. Among them, integrin a7 (ITGA7) was chosen for
further study because it was only expressed in a small group of
cancer cells in both clinical specimens and cell lines. Integrins are
transmembrane cell surface receptors comprised of 18 a and 8 b
subunits. Integrins directly bind components of the extracellular
matrix (ECM) and provide the traction necessary for cell motility
and invasion. ITGA7, the receptor for the ECM protein laminin,
forms heterodimer with integrin b1. Integrins are involved in a
broad spectrum of cellular processes, including survival,
proliferation, migration and invasion18. Recent studies have
suggested that integrins play important roles in the regulation of
stem cell-like properties and enrich CSCs from glioblastoma
multiforme (GBM)19, breast cancer20 and prostate cancer21.
In the present study, we ﬁnd that ITGA7þ cells to be
sporadically expressed in clinical OSCC specimens and that the
presence of ITGA7þ cells is closely correlated with aggressive
tumour behaviour and poor outcome. Functional studies
demonstrate that ITGA7þ cells possess strong CSC properties
including abilities to self-renew, differentiate and resist
chemotherapy. The molecular mechanism by which ITGA7
regulates these properties is also elucidated. Our data indicate that
ITGA7 is a potential CSC marker in OSCC with function in
stemness regulation.
Results
ITGA7þ cells are markedly associated with poor outcome.
Expression of ITGA7 was analyzed by immunohistochemistry
(IHC) on a tissue microarray (TMA) consisting of 300 paired
OSCC and non-tumour clinical samples. Informative IHC results
were obtained from 262 pairs of OSCCs. Non-informative
samples included lost samples and unrepresentative samples,
which were not included in data complication. ITGA7-expressing
cells were detected in most of these informative OSCC cases, with
expression ranging from 0 to 5%; while ITGA7 expression could
not be detected in any of the corresponding non-tumour tissues
(Fig. 1a). On the basis of the frequency of ITGA7 positive cells
(ITGA7þ ), the OSCC patients were almost equally divided
into high-frequency group (40.6%, n¼ 137, 52.3%) and
low-frequency group (r0.6%, n¼ 125, 47.7%) (Supplementary
Table 1). Association study found that the high-frequency
group was signiﬁcantly associated with poor differentiation
(Pearson w2 test, P¼ 0.001), presence of invasion (Pearson w2 test,
P¼ 0.009), advanced clinical stage (Pearson w2 test, Po0.001)
and lymph node metastasis (Pearson w2 test, P¼ 0.005; Table 1).
Kaplan–Meier survival analysis based on this TMA data found
that OSCC patients with high frequency of ITGA7þ cells
(40.6%) were signiﬁcantly associated with a shorter survival time
(log-rank test, Po0.001; Fig. 1b). Next, we used ﬂow cytometry
to detect the frequency of ITGA7þ cells in 2 immortalized
oesophageal epithelial cell lines (NE1 and NE3) and 10 OSCC cell
lines. The result showed that the frequency of ITGA7þ cells in
OSCC cell lines (except EC109) was much higher than that
in immortalized oesophageal epithelial cell lines (Fig. 1c;
Supplementary Fig. 1a). This result was further conﬁrmed by
immunoﬂuorescence in NE1, EC109, KYSE180 and KYSE520 cell
lines (Supplementary Fig. 1b).
Non-CG methylation is mainly detected in ITGA7þ OSCC cells.
Since non-CG methylation plays important roles in the tran-
scriptional regulation of target genes in stem cells, we next
investigated whether ITGA7 expression was up-regulated in this
manner. Three DNA fragments within ITGA7 gene containing
CG and non-CG methylation loci were selected based on
epigenetic modiﬁcation data between ESC and fetal ﬁbroblasts
(http://neomorph.salk.edu/human_methylome). Bisulﬁte geno-
mic sequencing (BGS) analysis was performed in sorted ITGA7þ
and ITGA7 cells from KYSE180 and KYSE520 cell lines. The
result showed that ITGA7þ cells displayed much higher non-CG
methylation frequency than their negative counterparts, implying
that ITGA7 expression might be correlated with non-CG
methylation (Fig. 1d). To determine whether the expression of
ITGA7 could be restored by DNA demethylation, a DNA
methylation inhibitor 5-aza-20-deoxycytidine was used to treat
sorted ITGA7þ and ITGA7 cells. After treatment, expression
of ITGA7 was signiﬁcantly increased (Fig. 1e).
ITGA7 and CD90 is co-expressed in OSCC. CD90 has pre-
viously been reported by our group to phenotypically mark a
functionally deﬁned oesophageal CSC subset10. To examine
whether CD90 and ITGA7 is co-expressed, dual-colour ﬂow
cytometry was performed to examine their expression in a panel
of oesophageal cell lines (Supplementary Fig. 2). Our ﬁndings
included: (1) the frequencies of ITGA7þ cells and CD90þ cells
were in the same trend (Fig. 2a; Supplementary Table 2); (2)
ITGA7þ cells were much less abundant than CD90þ cells in all
oesophageal cell lines; and (3) most ITGA7þ cells in OSCC cell
lines were also CD90þ (Supplementary Table 3). To conﬁrm that
ITGA7 was co-expressed with CD90, cryosectioned spheroids
generated from KYSE520 cells were stained and analyzed by
immunoﬂuorescence. The result showed that most of ITGA7þ
cells were co-expressed with CD90 (Fig. 2b). These ﬁndings
suggested that ITGA7þ cells may represent and mark a more
speciﬁc oesophageal CSC subset than CD90. To validate this,
CD90þ /ITGA7þ , CD90þ /ITGA7 and CD90 /ITGA7 cells
were separated from KYSE520 cells by cell sorting, while
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13568
2 NATURE COMMUNICATIONS | 7:13568 | DOI: 10.1038/ncomms13568 | www.nature.com/naturecommunications
CD90 /ITGA7þ subpopulation does not exist because most
ITGA7þ cells are also CD90þ (Fig. 2c). Western blot analysis
demonstrated that the expression of stemness-associated genes
was markedly higher in CD90þ /ITGA7þ cells than that in
CD90þ /ITGA7 or CD90 /ITGA7 cells (Fig. 2d). Spheroid
formation assay also found that the self-renewal ability
was signiﬁcantly enhanced in CD90þ /ITGA7þ cells, compared
with CD90þ /ITGA7 and CD90 /ITGA7 cells (Fig. 2e).
In addition, CD90þ /ITGA7þ cells were able to induce more and
bigger colonies than those induced by CD90þ /ITGA7 and
CD90 /ITGA7 cells (Fig. 2f).
ITGA7þ OSCC cells possess CSC properties. To further con-
ﬁrm ITGA7þ OSCC cells are CSCs, major cancer and stemness
properties including expression of stemness-associated genes and
abilities to self-renew, differentiate and resist chemotherapy were
analyzed in ITGA7 sorted subsets isolated from KYSE180 and
KYSE520 cells. ITGA7þ cells expressed higher levels of OCT3/4,
SOX2, NANOG and CD90, compared with ITGA7 cells
(Fig. 3a). Further, ITGA7þ cells displayed signiﬁcantly enhanced
ability to initiate spheroid formation and to expand in subsequent
serial propagations, compared with ITGA7 cells, demonstrating
their increased ability to self-renew (Fig. 3b).
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Figure 1 | High frequency of ITGA7þ cells is signiﬁcantly associated with poor outcome in OSCC. (a) Representative IHC images show that ITGA7þ
cells were scattered in OSCC tumour tissue in clinical specimen, but not in non-tumour tissue. Scale bar, 100mm. (b) Kaplan–Meier survival analysis shows
that OSCCs with high frequency of ITGA7þ cells (40.6%, ITGA7þ , n¼ 137) had shorter survival time, compared with OSCCs with low frequency of
ITGA7þ cells (r0.6%, ITGA7 , n¼ 125). (c) Percentage of ITGA7þ cells detected by FACS in immortalized esophageal epithelial and OSCC cell lines.
The average percentage of ITGA7þ cells, the mean±s.d. of three independent detections, in different cell lines was depicted in the bar chart. (d) Detection
of DNA methylation in the CG and CH context (H¼A, C or T) by genomic bisulﬁte sequence. Non-CG methylation of ITGA7 preferred to occur in
ITGA7þ cells isolated from KYSE180 and KYSE520. (e) qRT-PCR showed that the expression of ITGA7 was markedly increased after treated with
5-aza-20-deoxycytidine (5-aza-dC, 50mM) for 3 days. Statistics: (c,e) ANOVA with post hoc test. *Po0.05; **Po0.001; ***Po0.0001; n.s., PZ0.05.
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To investigate the differentiation potential of ITGA7þ cells,
differentiation inducer all-trans retinoic acid (atRA) was used to
treat ITGA7þ and ITGA7 cells. Western blot analysis showed
that atRA treatment could effectively induce the differentiation of
ITGA7þ cells by increasing CK13 (a marker of differentiated
supra basal cells) and decreasing CK14 (a marker of oesophageal
basal cell) expression. Consequently, the expression of ITGA7
and stemness-associated genes OCT3/4, SOX2 and NANOG was
also decreased (Fig. 3c). However, no expression change was
observed in ITGA7 cells after atRA treatment. This data
demonstrated that ITGA7þ cells possessed differentiation ability.
To check whether ITGA7þ cells are more chemoresistant,
chemotherapeutic reagents cisplatin and 5-ﬂuorouracil (5-FU)
were used to treat ITGA7 and ITGA7þ OSCC cells. Flow
cytometry analysis showed that the apoptotic/necrotic cells were
signiﬁcantly higher in ITGA7 cells compared with ITGA7þ
cells (Fig. 3d), indicating that ITGA7þ cells were more resistant
to the chemotherapeutic drugs. To further investigate the in vivo
tumorigenic potential of ITGA7þ cells, ITGA7þ and ITGA7
cells were subcutaneously engrafted in NOD/SCID mice,
respectively. As few as 10,000 ITGA7þ cells were sufﬁcient to
generate visible tumours 4 months post injection, whereas, at least
100,000 ITGA7 cells were necessary to generate a tumour in the
same mouse model (Fig. 3e; Table 2).
Knockdown of ITGA7 reduces CSC properties in OSCC cells.
To further investigate if ITGA7 is a functional marker of oeso-
phageal CSCs, we performed similar assays to examine cancer
and stemness properties in OSCC cells with ITGA7 stably sup-
pressed. Expression of ITGA7 in KYSE180 and KYSE520 cells
was silenced with ITGA7-speciﬁc short hairpin RNA (shRNA).
Cells treated with scrambled shRNA were used as non-target
controls (NTC). After conﬁrmation of successful knockdown
with a 60% reduction by ﬂow cytometry (Fig. 3f) and western
blotting (Fig. 3g), we ﬁrst detected the expression of stemness-
associated genes. Compared with cells treated with scrambled
shRNA, OCT3/4, SOX2 and NANOG were down-regulated in
shITGA7-treated cells (Fig. 3g). To determine whether ITGA7
knockdown could affect chemoresistant potential, cisplatin and
5-FU were used to treat shITGA7-transfected cells. The apoptotic
index of shITGA7-transfected OSCC cells was signiﬁcantly higher
than that of control cells after a 48-h exposure to chemother-
apeutic reagents (Fig. 3h; Supplementary Fig. 3). Spheroid
formation assay showed that shITGA7-transfected KYSE180 and
KYSE520 cells formed smaller and less spheroids, compared with
control cells (Fig. 3i). In view of the importance of ITGA7 in
regulating differentiation, western blot analysis was used to detect
expression level of well differentiation marker CK13 and poor
differentiation marker CK14 in OSCC. The result showed that
ITGA7 could up-regulate CK14 and down-regulate CK13
expression (Fig. 3j). To investigate the in vivo tumorigenic
potential of ITGA7 knockdown cells, scrambled shRNA
and shITGA7-treated cells were subcutaneously engrafted in
NOD/SCID mice, respectively. To minimize the number of mice
to be used, two ITGA7-speciﬁc shRNAs-treated cells were equally
mixed together as shITGA7 group. Compared with control group,
knockdown of ITGA7 could effectively suppress tumour initiation
(Table 3).
Ectopic overexpression of ITGA7 enhances CSC properties.
As a complementary model, ITGA7 was also stably transfected
into EC109 and KYSE30 cells. Expression level of ITGA7 in
ITGA7-transfected cells was determined by western blotting
(Fig. 4a) and ﬂow cytometry (Fig. 4b). Western blotting results
also showed that the ectopic expression of ITGA7 could enhance
expression of stemness-associated genes (Fig. 4a). To examine
whether the ectopic expression of ITGA7 could affect
chemoresistant potential, cisplatin and 5-FU were used to
treat ITGA7-transfected cells. The apoptotic index of ITGA7-
transfected cells was signiﬁcantly lower than that of control cells,
which is similar to sorted ITGA7þ cells (Fig. 4c). Spheroid
formation assay showed that ITGA7-transfected cells formed
signiﬁcantly larger and more spheroids, compared with control
cells (Fig. 4d). Ectopic overexpression of ITGA7 resulted in a
marked decrease in the well-differentiated marker CK13. Note
EC109 did not express CK13 and neither cell lines expressed
CK14, and thus deregulation in expression could not be tested
(Fig. 4e).
The tumorigenic ability of ITGA7 was assessed by foci
formation and soft agar assays. Compared with control cells,
ITGA7-expressing cells displayed higher foci formation frequen-
cies (Fig. 4f) and enhanced colony forming abilities in soft agar
(Fig. 4g). To further investigate the in vivo tumorigenic ability of
ITGA7, ITGA7-transfected cells and control cells were subcuta-
neously injected into the right and left dorsal ﬂank of NOD/SCID
mice, respectively. The result found that ITGA7-overexpressed
EC109 and KYSE30 cells displayed signiﬁcantly stronger tumour
initiation ability than their control cells (Fig. 4h; Table 3).
ITGA7 promotes metastasis by inducing EMT. As high fre-
quency of ITGA7þ cells was clinically associated with tumour
invasion and metastasis, the effect of ITGA7 on metastasis was
further studied. Cell migration and invasion assays showed that
ITGA7þ cells could signiﬁcantly promote cell migration and
invasion abilities, as compared with ITGA7 cells (Fig. 5a;
Supplementary Fig. 4a). To investigate the effect of ITGA7 on cell
mobility, wound healing assay was performed in ITGA7 up-
regulated cells and down-regulated cells. The result showed that
ITGA7 could markedly enhance tumour cell mobility
(Supplementary Fig. 4b). Cell migration and invasion assays also
displayed that ITGA7-transfected cells could promote cell
migration and invasion abilities, as compared with control cells
Table 1 | Association of ITGA7 expression with
clinicopathologic features in 262 primary OSCC cases.
Features Total ITGA7 expression* P-valuew
Low
frequency
High
frequency
Sex 0.390
Male 150 75 (50%) 75 (50%)
Female 112 50 (44.6%) 62 (55.4%)
Age 0.593
o60 138 68 (49.3%) 70 (50.7%)
Z60 124 57 (46%) 67 (54%)
Differentiation 0.001z
Well/moderate 195 105 (53.8%) 90 (46.2%)
Poor 67 20 (29.9%) 47 (70.1%)
Tumour stagey o0.001z
Early stage I–II 170 96 (56.5%) 74 (43.5%)
Advanced stage III–IV 92 29 (31.5%) 63 (68.5%)
Invasion 0.009z
Absent 90 53 (58.9%) 37 (41.1%)
Present 172 72 (41.9%) 100 (58.1%)
Lymph-node metastasis 0.005z
Absent 142 79 (55.6%) 63 (44.4%)
Present 120 46 (38.3%) 74 (61.7%)
*ITGA7 percentage r0.6% as low frequency; 40.6% as high frequency.
wPearson w2 test.
zSigniﬁcance.
yAJCC/UICC TNM staging system.
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(Supplementary Fig. 4c). Once endogenous ITGA7 was silenced
by shRNA, the abilities of cell migration and invasion were sig-
niﬁcantly inhibited (Fig. 5b). To further investigate the effect of
ITGA7 on tumour metastasis, a lymph node metastasis animal
model was performed by injecting ITGA7-transfected KYSE30
cells into right hind foot-pad of NOD/SCID mice. Empty vector-
transfected cells were used as controls. In the lymph node
metastasis model, popliteal lymph nodes, which represent the
sentinel lymph node for the model, were examined22. Swollen
popliteal lymph nodes were observed in all seven mice injected
with ITGA7-transfected cells, and lymph node metastasis was
conﬁrmed by H&E staining in all seven mice. Only one-seventh
of mice injected with control cells displayed tumour metastasis
(Fig. 5c).
Morphological change from round shape to spindle-like shape
was observed in ITGA7-transfected cells, suggesting that these
cells may undergo epithelial–mesenchymal transition (EMT)
(Fig. 5d). To investigate whether this morphological change
was caused by EMT, immunoﬂuorescence was performed to test
some representative epithelial (E-cadherin and b-catenin) and
mesenchymal (ﬁbronectin and vimentin) markers. Compared
with control cells, expression of E-cadherin was decreased in
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Figure 2 | ITGA7 and CD90 is co-expressed in OSCC and marks a more tumorigenic OSCC subpopulation. (a) Summary of the overlap of ITGA7þ and
CD90þ cells in esophageal cell lines detected by dual-colour ﬂow cytometry. (b) Representative dual-colour immunoﬂuorescence analyses of
cryosectioned spheroids generated from KYSE520 showing the co-localization of ITGA7 (green) and CD90 (red). Scale bar, 50 mm. (c) Representative
dual-colour ﬂow cytometry analysis of KYSE520 cells for ITGA7 and CD90. The cells (dot plots) were divided into four quadrants as indicated and collected
for each quadrant as gated in the red boxes. CD90/ITGA7þ subpopulation does not exist because most ITGA7þ cells are also CD90þ . Freshly isolated
subpopulations were detected by western blotting analysis (d), and subjected to spheroid formation assay (e, Scale bar, 500mm) and soft agar colony
formation assay (f, Scale bar, 500mm). Data are represented as mean±s.d. of three separate experiments. Statistics: (e,f) ANOVA with post hoc test.
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ITGA7-KYSE30 cells. Although the expression level of b-catenin
was similar, its nuclear accumulation was observed in ITGA7-
transfected cells. Expression of mesenchymal markers ﬁbronectin
and vimentin was elevated in ITGA7-KYSE30 cells (Fig. 5d). The
immunoﬂuorescence result was further conﬁrmed by western blot
analysis. Compared with negative counterparts, the expression
level of mesenchymal markers was markedly increased in ITGA7-
transfected cells and ITGA7þ cells, while the expression of
E-cadherin was decreased in ITGA7-transfected KYSE30 cells and
KYSE520 ITGA7þ cells, no signiﬁcant difference was observed in
ITGA7-transfected EC109 cells and KYSE180 ITGA7þ cells;
maybe the regulation of E-cadherin is cell line speciﬁc (Fig. 5e).
Conversely, ITGA7 knockdown displayed a reverse tread in
expression of epithelial and mesenchymal markers (Fig. 5f).
ITGA7 drives CSC features via the FAK/MAPK/ERK signalling.
As focal adhesion kinase (FAK) is a major downstream target
activated by integrins, we next studied whether ITGA7 can
activate FAK and the corresponding FAK/MAPK/ERK pathway.
Compared with ITGA7 cells, ITGA7þ cells displayed an
enhanced phosphorylation of FAK, Src and c-Raf with a
concomitant increase in the downstream phosphorylation of
MEK1/2 and ERK (Fig. 6a). To conﬁrm the FAK/MAPK/ERK
pathway could be activated by ITGA7, we also tested the
expression of activated kinases in this signalling cascade in
ITGA7-transfected EC109 and KYSE30 cells. The results
demonstrated that the FAK/MAPK/ERK pathway could be
activated by ITGA7 (Fig. 6b). Consistently, decreased
phosphorylation of FAK, Src, c-Raf, MEK1/2 and ERK was
observed when ITGA7 was silenced (Fig. 6c).
To further conﬁrm the effect of ITGA7 on cancer
stemness is through the FAK-mediated pathway, we studied
whether a speciﬁc FAK autophosphorylation inhibitor Y15
(1,2,4,5-benzenetetraamine tetrahydrochloride) could abolish
ITGA7-induced tumorigenicity and metastasis. Addition of Y15
effectively reduced FAK activity and ERK phosphorylation in
ITGA7-transfected KYSE30 cells (Fig. 6d). Functional assays also
found that the treatment of Y15 could signiﬁcantly inhibit
spheroid formation (Fig. 6e), cell migration (Fig. 6f) and invasion
abilities (Fig. 6g), and down-regulated expression of OCT3/4,
SOX2 and NANOG (Fig. 6h), as compared with untreated cells.
Moreover, to investigate whether MAPK/ERK is the downstream
player of ITGA7, we also treated ITGA7-KYSE30 cells with
MEK1/2 inhibitor U0126. After treatment, the phosphorylation of
MEK1/2 and ERK decreased markedly in ITGA7-treasfected cells
(Supplementary Fig. 5a). Functional study showed that U0126
treatment signiﬁcantly suppressed foci formation (Supplementary
Fig. 5b), cell migration (Supplementary Fig. 5c) and invasion
abilities (Supplementary Fig. 5d), as compared with untreated
cells. Taken together, these results suggested that ITGA7
functionally conferred cancer stemness features in OSCC via
activation of the FAK/MAPK/ERK pathway.
Chemotherapy enriches ITGA7þ CSCs in clinical OSCC
tumours. To obtain further evidence in support of our hypothesis
that ITGA7þ cells confer chemoresistance in OSCC tumours, we
established a chemoresistant OSCC xenograft model by treating
KYSE520 subcutaneously developed tumours in NOD/SCID mice
with varying doses of cisplatin from 0 to 5mg kg 1. Such
treatment resulted in variable tumour inhibition among the
xenografts, in a dose-dependent trend. From the dose–response
curve, we found that the dosage of 2.5 or 5mg kg 1 cisplatin
could effectively shrink the tumour size (Fig.7a). Interestingly,
IHC result showed that the frequency of ITGA7þ cells was
markedly enriched in cisplatin-treated tumours (Fig. 7b). Further,
cisplatin-treated OSCC xenografts also displayed enhanced
expression of stemness-associated genes as well as ITGA7 in a
dose-dependent manner (Fig. 7c). Consistently, OSCC cells
derived from chemoresistant group exhibited markedly enhanced
ability to form spheroids, compared with the tumour cells from
control group (Fig. 7d).
We next studied whether chemotherapy could enrich ITGA7þ
cells in clinical OSCC specimens by IHC staining. To fulﬁl this
purpose, 22 and 28 clinical OSCC samples were collected from
patients that had or had not undergone chemotherapy before
esophagectomy, respectively. Percentage of ITGA7þ cells
(5.64±4.15%) was signiﬁcantly enriched in tumours treated with
chemotherapy, as compared with tumours without (0.64±0.74%)
(Fig. 7e). This ﬁnding suggests that ITGA7þ cells possess strong
chemoresistant ability that causes their enrichment in OSCC
tumours after chemotherapy.
ITGA7 inhibits apoptosis via activating FAK/Akt signalling.
To investigate the underlying mechanism of ITGA7-mediated
chemoresistance, we studied FAK downstream signalling pathway
PI3K/Akt, a well-known pathway that mediates cell survival.
Table 2 | Tumour incidence rate induced by ITGA7 and
ITGA7þ OSCC cells.
Cells injected KYSE180
ITGA7þ
KYSE180
ITGA7
KYSE520
ITGA7þ
KYSE520
ITGA7
5,000 1/4 0/4 0/4 0/4
10,000 1/4 0/4 1/4 0/4
50,000 3/4 0/4 2/4 0/4
100,000 4/4 1/4 4/4 0/4
300,000 4/4 3/4 4/4 2/4
Tumour-initiating
frequency*
1/28,733 1/242,532 1/46,830 1/770,323
P value* P¼0.0003 Po0.0001
*Limiting dilution analysis.
Table 3 | Tumour incidence rate induced by indicated OSCC cells.
Cells injected KYSE180
NTC versus shA7
KYSE520
NTC versus shA7
EC109
EV versus ITGA7
KYSE30
EV versus ITGA7
10,000 1/4 versus 0/4 0/4 versus 0/4 0/4 versus 1/4 0/4 versus 0/4
50,000 1/4 versus 1/4 1/4 versus 0/4 0/4 versus 3/4 0/4 versus 3/4
100,000 4/4 versus 2/4 3/4 versus 1/4 1/4 versus 3/4 1/4 versus 3/4
300,000 4/4 versus 3/4 4/4 versus 2/4 3/4 versus 4/4 4/4 versus 4/4
Tumour-initiating frequency* 1/57,411 versus 1/190,259 1/95,663 versus 1/485,851 1/316,851 versus 1/49,618 1/209,502 versus 1/59,441
P value* P¼0.0429 P¼0.016 P¼0.0026 P¼0.041
*Limiting dilution analysis.
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Activated Akt can phosphorylate a wide variety of substrate
proteins to maintain the integrity of the mitochondrial mem-
brane, which blocks cytochrome c release and subsequent caspase
activation and apoptosis. Therefore, we studied whether ITGA7
could inhibit apoptosis via the FAK/PI3K/Akt signalling. The
result found that phosphorylation of FAK and Akt was increased
in ITGA7þ OSCC cells and ITGA7-transfected cells on cisplatin
stimulation, as compared with control cells (Fig. 7f). As a result,
ITGA7þ cells and ITGA7-transfected cells maintained a high
inner mitochondrial transmembrane potential (DCm) (shown in
red ﬂuorescent), whereas most of the control cells underwent a
proapoptotic mitochondrial permeability transition (Fig. 7g).
ITGA7-induced Akt phosphorylation protected the mitochon-
drial membrane from cisplatin-induced collapse, thereby blocking
the release of cytochrome c into the cytoplasm, and the cleavages
of caspase-9, caspase-3 and PARP (Fig. 7f). The anti-apoptotic
phenotype and Akt phosphorylation could be effectively reversed
when ITGA7 was silenced in KYSE520 cells. Reduced phos-
phorylated Akt in ITGA7 silenced cells led to DCm collapse
(Fig. 7g). As a result, cleaved forms of caspase-9, caspase-3 and
PARP increased in ITGA7 silenced cells compared with control
cells (Fig. 7f).
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Figure 5 | ITGA7 promotes metastasis by inducing EMT. (a) Representatives and summary of migration and invasion assays showing that ITGA7þ cells
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Discussion
So far, the CSCs have been functional deﬁned in a wide variety of
solid tumours using extensive markers, including brain, breast,
colon, liver and prostate cancers. However, there are several
important questions that remain understudied. One question is
how sensitive and speciﬁc these CSC markers are in marking
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Figure 6 | ITGA7 drives cancer stemness features in OSCC via the FAK/MAPK/ERK signalling. (a–c) Western blot analyses showed that the FAK/
MAPK/ERK pathway was activated in sorted ITGA7þ cells and ITGA7-transfected cells, while inhibited in ITGA7 silencing cells. b-Actin was used as a
loading control. (d) Western blot analyses showed that the phosphorylation of FAK and downstream player Erk1/2 was signiﬁcantly blocked in ITGA7-
transfected KYSE30 cells after treatment with 7.5mM FAK inhibitor Y15. Functional assays demonstrated that Y15 treatment could effectively inhibit
spheroid formation ability (e; 500mm scale bar), cell migration ability (f; 200mm scale bar), cell invasion ability (g; 200mm scale bar) and the expression
of stemness-related genes in ITGA7-transfected cells (h). The number of spheroids and migrated or invaded cells was calculated from three independent
experiments and depicted as the mean±s.d. in the bar chart. Statistics: (e–h) ANOVA with post hoc test. *Po0.05; **Po0.001; n.s., PZ0.05.
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Figure 7 | ITGA7 promotes chemoresistance via the FAK/Akt/Caspase-9/Caspase-3 pathway. (a) NOD/SCID mice with xenograft tumours of 5mm in
diameter were randomly separated into four groups and treated with varying doses of cisplatin. The doses of 2.5 and 5mg kg 1 cisplatin could effectively
suppress tumour growth and shrink tumour size. The average tumour volume was expressed as the mean±s.d. of three mice. (b) Representative IHC
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ITGA7 and stemness-associated genes was positively correlated with the dosage of cisplatin. (d) Representatives and summary of spheroid formation
assay showing that isolated cells from chemoresistant group displayed enhanced self-renewal ability. Scale bar, 500mm. (e) Representative images of
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CSCs? Another question is the heterogeneity of CSCs in a given
cancer. For example, surface markers CD90 (ref. 10), CD44
(ref. 12) and p75NTR (ref. 13), have been used for CSCs isolation
in OSCC. Does this suggest that different CSC subsets may be
derived from different cell of origins, or just in different
hierarchical levels? The key issue behind these questions is to
identify one speciﬁc protein that plays role in regulating stemness
and CSC maintenance. Ideally, the optimized marker for CSC
should have a function in maintaining CSC in a stem cell state,
therefore, the marker should not be lost from the CSC without
losing the stem cell properties. As a result, focus has been placed
on enzymes or proteins, which can directly associate with CSC
maintenance, such as ALDH1 (ref. 23) and ABCB5 (ref. 24). The
identiﬁcation of functional CSC markers has also focused on
signalling pathways with an indispensable role in normal stem
cell biology, such as Hedgehog25 and integrin signalling19–21.
In the present study, we aimed to identify a novel functional
CSC marker in OSCC. Non-CG methylation has been conﬁned as
a characteristic of stem cells14,15, and several essential stemness-
associated genes, such as NANOG, SOX2 and OCT3/4 have been
found highly modiﬁed with non-CG methylation in stem cells. It
suggests that non-CG methylation may regulate transcriptional
activity only in CSCs, but not in non-CSC. Here, we found that
non-CG methylation preferentially presented in ITGA7þ rather
than ITGA7 OSCC cells, implying that the transcriptional
activity of ITGA7 might be also regulated by non-CG
methylation. ITGA7 gene encodes for an ECM receptor integrin
a7 that belongs to the integrin family. Recent studies indicate that
some integrin family members, such as integrin a6 (ref. 19) and
b1 (ref. 26), play critical roles in maintaining stem cell niche,
preserving a stable stem cell population, and regulating stem cell
homoeostasis27. In clinical OSCC specimens, ITGA7þ cells
were expressed in o1% of tumour cells in most tumour tissues
(203/262, 77.5%), which was consistent with CSC expectation.
Interestingly, high-frequency ITGA7þ cells (40.6%) was
signiﬁcantly associated with OSCC stemness such as cell
differentiation, advanced clinical stage, tumour invasion and
lymph node metastasis, suggesting that ITGA7 might play roles in
regulating stemness.
Compared with a known oesophageal CSC marker CD90,
the population of ITGA7þ cells was much smaller than the
population of CD90þ cells in both immortalized oesophageal
and OSCC cell lines. Interestingly, most of ITGA7þ cells were
co-expressed with CD90, while only part of CD90þ cells
co-expressed with ITGA7 in OSCC cell lines. Functional study
found that ITGA7þ /CD90þ cells possessed stronger stemness
compared with ITGA7 /CD90þ cell, implying that ITGA7þ
cells might be more properly represent CSCs in OSCC. Further
functional assays were used to characterize ITGA7þ cells sorted
from KYSE180 and KYSE520 cells. Compared with ITGA7
cells, ITGA7þ cells showed stronger abilities for self-renew, cell
differentiation, cell motility and chemoresistance, as well as with
higher expression of stemness-associated genes. In addition,
ITGA7-transfected cells also possessed CSC properties. We also
found ITGA7þ OSCC cells underwent EMT, which is respon-
sible for initiation of metastasis28,29. All these CSC properties
could be effectively inhibited when ITGA7 was silenced by
shRNA. All these ﬁndings suggest that ITGA7 is a better CSC
marker with stemness regulatory function. As expression level of
ITGA7 was extremely low in clinical specimens, these functional
assays could not be repeated in clinical samples. Further study
found that the effects of ITGA7 on OSCC development might be
through the activation of FAK/MAPK/ERK signalling pathway,
which has been reported to be involved in a series of tumour
processes30. Similar to ITGA7 knockdown, FAK inhibitor could
also inhibit the effect of ITGA7 on self-renewal ability and
decrease the expression of stemness-associated genes such as
OCT3/4, SOX2 and NANOG. Recently, Golubovskaya31 reported
the interaction of FAK, NANOG, OCT3/4 and SOX2 played a
critical role in regulating CSCs. This suggests that ITGA7 might
be involved in stemness regulation and CSC maintenance in
OSCC through the activation of FAK/MAPK/ERK signalling
pathway.
One of the important characteristics of CSCs in clinical
point of view is its resistance to conventional chemotherapy. In
the present study, we demonstrated that ITGA7þ cells were
markedly enriched in residual OSCC xenograft tumours in
NOD/SCID mice after treatment with cisplatin chemotherapy.
Consistent with this data, the enrichment of ITGA7þ cells was
also observed in clinical OSCC samples after chemotherapy. This
ﬁnding may help explain why chemotherapy fails to eradicate the
disease although it can effectively shrink the tumour size by
killing most of tumour cells. Therefore, development of novel
therapeutic strategy by targeting CSCs is necessary to cure cancer.
Further study found that ITGA7 exerted the anti-apoptotic effect
through the versatile player FAK to activate the Akt signalling,
which subsequently inhibited the release of cytochrome c into the
cytoplasm and the cleavages of caspase-9, caspase-3 and PARP. In
summary, we report here that ITGA7 is a potential CSC marker
in OSCC with function in stemness regulation and CSCs
maintenance. Further characterization of ITGA7 may provide
an alternative therapeutic approach by targeting CSCs to achieve
better clinical outcome.
Methods
OSCC clinical specimens. Three hundred pairs of primary OSCC specimens and
their adjacent non-tumour oesophageal tissues, used for a TMA, were collected
from patients who underwent oesophageal resection at Linzhou Cancer hospital
(Henan, China). Twenty-eight clinical specimens were collected from OSCC
patients at Sun Yat-Sen University Cancer Center (Guangzhou, China). None of
these patients received preoperative treatment. Twenty-two clinical specimens
were collected from patients with OSCCs who had received neoadjuvant chemo-
radiotherapy before operation at the Queen Mary Hospital (Hong Kong).
Histological examination was carried out by pathologists, and diagnosis was made
based on the microscopic features of the carcinoma cells. Tumours were graded
using the American Joint Committee on Cancer (AJCC)/International Union
Against Cancer (UICC) tumour staging system. Informed consent was obtained
from all patients before the collection of oesophageal specimens, and the study was
approved by the committees for ethical review of research involving human sub-
jects at Zhengzhou University (Zhengzhou, China), Sun Yat-Sen University
(Guangzhou, China) and the University of Hong Kong (Hong Kong).
Cell lines. Immortalized oesophageal epithelial cell lines NE1 and NE3 were
established in Professor George Tsao’s laboratory (Department of Anatomy, The
University of Hong Kong). Chinese OSCC cell lines HKESC1, EC18, EC109 and
EC9706 were kindly provided by Professor Srivastava (Department of Pathology,
The University of Hong Kong). Six Japanese OSCC cell lines (KYSE30, KYSE140,
KYSE180, KYSE410, KYSE510 and KYSE520) were obtained from DAMZ, the
German Resource Center for Biological Material. Mycoplasma contamination was
not found in these cell lines.
Animals. The study protocol was approved by and performed in accordance with
the Committee of the Use of Live Animals in Teaching and Research at the
University of Hong Kong. For in vivo tumorigenic experiment, various numbers of
ITGA7 sorted cells, ITGA7-transfected cells and ITGA7-suppressed cells were
injected subcutaneously into 4-to-5-week-old NOD/SCID mice. Mice were killed
between 2 and 4 months post injection. Those animals injected with tumour cells
but no sign of tumour burden were generally terminated 4 months after tumour
cell inoculation, and mice were opened up at the injection sites to conﬁrm that
there was no tumour development. For in vivo metastasis assay, each experimental
group consisted of seven 5-week-old NOD/SCID mice. Brieﬂy, 2 105 cells in 20ml
phosphate-buffered saline (PBS) were injected into the right hind foot-pad of each
mouse. All of the mice were euthanized 4 weeks after injection. The right side
popliteal lymph nodes were excised and embedded in parafﬁn. For chemoresistant
xenograft model, subcutaneous xenografts in 5-week-old NOD/SCID mice were
established with KYSE520 cells (1 106). Treatment was started once the size of
the xenograft reachedB5mm in diameter. The mice were randomly assigned into
four groups, each consisting of three mice. They were treated with cisplatin
intraperitoneally every 4 days for 24 days at different doses of 0, 1, 2.5 or
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13568
12 NATURE COMMUNICATIONS | 7:13568 | DOI: 10.1038/ncomms13568 | www.nature.com/naturecommunications
5mg kg 1. Tumour sizes were measured by caliper, and tumour volumes were
calculated as volume (mm3)¼ LW2 0.5. Cell dissociation from xenograft is
detailed in Supplementary Methods.
IHC. IHC staining was performed using the standard streptavidin–biotin–
peroxidase complex method. Brieﬂy, parafﬁn sections were deparafﬁnized and
rehydrated. Slides were heated for antigen retrieval for 15min in 10mM citrate
(pH 6). Sections were incubated with monoclonal mouse anti-human ITGA7
(1:100 dilution; Abgent) at 4 C overnight. EnVision Plus System-HRP (DAB;
DAKO) was used according to manufacturer’s instruction, and followed by Mayer’s
hematoxylin counterstaining. Stained slides were imaged on an AperioScanscope
CS imager (Vista, CA, USA).
Immunoﬂuorescence. Immunoﬂuorescence was performed on cell lines
and cryosectioned spheroids. First, cells on the coverslips were ﬁxed with
4% paraformaldehyde, and incubated with primary antibody (rabbit anti-ITGA7 or
mouse anti-CD90) overnight at 4 C. After washing, cells underwent incubation
with FITC- or PE-conjugated secondary antibodies for 1 h, and subsequently
counterstained with DAPI for 5min at room temperature (Roche Diagnostics).
All images were visualized under Leica DMRA ﬂuorescence microscope (Wetzlar,
Germany).
Flow cytometry and cell sorting. Flow cytometric analysis and cell sorting
was conducted using anti-human ITGA7 (Abgent), and PE-conjugated mouse
anti-human CD90 (BD Biosciences). Cells were gently detached in citric saline
buffer, and incubated in PBS containing 2% fetal bovine serum (FBS) with
either PE-conjugated primary antibody or primary antibody followed by a
FITC-conjugated secondary antibody. Isotype-matched mouse or rabbit
immunoglobulin served as controls to gate positive cells. Samples were
analyzed and sorted on BD LSR Fortessa Analyzer and FACSAria I Cell Sorter
(BD Biosciences), and data analyzed using FlowJo software (Tree Star). For ITGA7
cell sorting, only the top 10% most brightly stained or the bottom 15% most dimly
stained cells were gated as positive and negative populations, respectively. Cell
viability was assessed using trypan blue exclusion. Using antibodies listed in
Supplementary Table 4.
Western blot analysis. Quantiﬁed protein lysates were resolved on SDS–PAGE,
transferred onto a polyvinylidenediﬂuoride (PVDF) membrane (Millipore), and
then blocked with 5% non-fat milk in Tris-buffered saline-Tween 20 (TBS-T) for
1 h at room temperature. The blocked membrane was then incubated with primary
antibody at 4 C overnight. After washing with TBS-T, the membrane was
incubated for 1 h with horseradish peroxidase (HRP)-conjugated secondary
antibody. A complex of primary and secondary antibodies-labelled proteins were
detected by enhanced chemiluminescence (ECL) system (GE Healthcare) and
X-ray ﬁlm (GE Healthcare). b-actin was used as a housekeeping control. Using
antibodies listed in Supplementary Table 4. Full blots of Figs 3c and 7f are provided
in Supplementary Fig. 6.
DNA extraction and non-CG methylation analysis. Genomic DNA was extracted
from isolated ITGA7þ and ITGA7 cells by phenol–chloroform method followed
by bisulﬁte modiﬁcation using the EpiTECT Bisulﬁte Kit (Qiagen). BGS primers
were listed in Supplementary Table 5. The template was ampliﬁed by PCR for
35 cycles and then cloned into the pGEM-T Easy vector (Promega) and sequenced
as individual clones by Beijing Genomics Institute. The sequence data was analyzed
by BiQ analyzer (Max Planck Institute).
RNA extraction and quantitative real-time PCR. Total RNA was extracted
using TRIZOL Reagent (Invitrogen), and cDNA was synthesized using a reverse
transcription (RT)-PCR Kit (Roche) according to the manufacturer’s instructions.
Quantitative real-time PCR (qRT-PCR) was performed using the SYBR Green PCR
Kit (Applied Biosystems) and an ABI PRISM 7900 Sequence Detector (Applied
Biosystems). Speciﬁcity of primers was veriﬁed by dissociation curve analysis. Data
was analyzed using ABI SDS v2.4 software (Applied Biosystems). All qRT-PCR
reactions were performed in duplicates. Housekeeping gene GAPDH was used as
an internal control. Using primers listed in Supplementary Table 5.
Spheroid formation assay. Single cells were cultured in suspension in 24-well
polyHEMA (Sigma-Aldrich)-coated plates. Cells were grown in 300 ml of
serum-free DMEM/F12 medium (Invitrogen) supplemented with 4 mgml 1
insulin (Sigma-Aldrich), B27 (1:50; Invitrogen), 20 ngml 1 human recombinant
EGF (Sigma-Aldrich), 10 ngml 1 human recombinant basic FGF (Invitrogen).
Cells were replenished with 30 ml of supplemented medium every second day. For
serial passage of primary spheroids, the primary spheroids were collected and
dissociated to single cells using TrypLE Expression (Invitrogen). Following
dissociation, trypsin inhibitor (Invitrogen) was used to neutralize the reaction,
and cells were resuspended in DMEM/F12 medium with the above supplements.
Apoptosis assay. Cells were treated with cisplatin or 5-FU (KYSE180 with
6 mgml 1 cisplatin or 12 mgml 1 5-FU; KYSE520 with 10mgml 1 cisplatin or
30 mgml 1 5-FU; EC109 with 4 mgml 1 cisplatin or 20 mgml 1 5-FU; and
KYSE30 with 1 mgml 1 cisplatin or 5 mgml 1 5-FU) for 48 h. Cells then were
collected and stained with propidium iodide (PI), and FITC-conjugated Annexin-V
provided by the Annexin-V FLUOS Staining Kit (Roche Diagnostics) according to
manufacturer’s instructions. Analysis was determined by ﬂow cytometry on a LSR
Fortessa Analyzer (BD Biosciences) and FlowJo software (Tree Star).
Differentiation assay. atRA (listed in Supplementary Table 6) was used to treat
sorted ITGA7 and ITGA7þ cells at a concentration of 20 or 30 mM in RPMI
1640 medium supplemented with 10% FBS and 1% penicillin and streptomycin for
5 days, with medium change daily. Expression change of ITGA7, differentiation
markers CK13 and CK14, and stemness-associated genes, was assessed by western
blot analysis.
In vitro tumorigenic assays. Anchorage-dependent growth was assessed by foci
formation assay. Brieﬂy, 2 103 cells were seeded in a 6-well plate. Surviving
colonies (450 cells per colony) were stained with 1% crystal violet (Sigma-Aldrich)
and counted after 1 week. Anchorage-independent growth was assessed by colony
formation in soft agar. In brief, 5 103 cells mixed thoroughly in 0.35% low
melting soft agar (BD Biosciences) were grown in a 6-well plate precoated with
0.5% agar. After 2 weeks, colonies (Z10 cells) were counted under microscope in
10 ﬁelds per well and photographed.
ITGA7 overexpression and knockdown. ITGA7 overexpression plasmid was
kindly provided by Dr. Jianhua Luo (Department of Pathology, University of
Pittsburgh School of Medicine). Brieﬂy, the full-length wild-type ITGA7 cDNA
(NM_002206.2) was cloned into the pLenti6 expression vector (Invitrogen) and
transfected into EC109 and KYSE30 cells with Lipofectamine 2000 Reagent
(Invitrogen). Stable ITGA7-expressing clones were selected for 2 weeks with
blasticidin (Sigma-Aldrich). EV-transfected cells were used as controls. For ITGA7
knockdown, the scrambled shRNA plasmid (pLKO.1-NTC) and the ITGA7-specﬁc
shRNA expression vectors (pLKO.1-shITGA7) were purchased from Sigma-Aldrich.
Two constructs against ITGA7 were used: shITGA7-1 (TRCN0000057708) and
shITGA7-3 (TRCN0000057711). The shRNA sequences listed in Supplementary
Table 7. The pLKO.1-shITGA7 or the scrambled shRNA plasmid was transfected
into KYSE180 and KYSE520, and stable clones were selected using puromycin
(Sigma-Aldrich).
Migration and invasion assays. Migration and invasion assays were performed in
24-well millicell hanging insert (Millipore) or 24-well BioCoat Matrigel Invasion
Chambers (BD Biosciences). In brief, 1 105 cells were seeded to the top chamber
and 10% FBS in medium was added to the bottom chamber as a chemoattractant.
After 24 or 48-h incubation, the number of cells that invaded through the
membrane (migration) or Matrigel (invasion) was counted in 10 ﬁelds and imaged
using SPOT imaging software (Nikon).
Mitochondrial membrane potential assay. The mitochondrial membrane
potential (DCm) was detected with a MitoPTJC-1 detection kit (Immunochemistry
Technologies) according to the manufacturer’s protocol. In brief, cells were seeded
onto coverslips and cultured to 80% conﬂuence; then 4 mgml 1 cisplatin was
added to treat cells for 24 h. The cells were washed twice with PBS and incubated
with the DCm-sensitive dye JC-1 at 37 C for 15min. Images were visualized
immediately under Leica DMRA ﬂuorescence microscope (Wetzlar, Germany).
Statistics. Statistical analysis was carried out with SPSS v. 16 (Chicago, IL, USA).
Pearson w2 test was used to analyze the association of ITGA7 expression with
clinicopathologic parameters. Kaplan–Meier plot and log-rank test were used for
survival analysis. Independent Student t-test and ANOVA with post hoc test
were used for most studies as indicated in the ﬁgure legends. For limiting dilution
assay, the tumour-initiating frequency and statistics were calculated using ELDA
software32. The data are presented as the mean±s.d. of three independent
experiments. The P-values were denoted as *Po0.05, **Po0.001 and ***Po0.0001
in all ﬁgures.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon request.
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